Periodic Reporting for period 2 - HemAcure (Application of combined gene and cell therapy within an implantable therapeutic device for the treatment of severe hemophilia A)

The long-term goal of HemAcure was to develop and refine tools and technologies for a novel ex vivo prepared cell-based therapy to treat the bleeding disease, haemophilia A (a genetic deficiency in clotting factor VIII (FVIII)) that ultimately lead to improved life quality of...